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Effects of phenolic acids on gastrointestinal smooth muscle
complications in streptozotocine-induced diabetic rats
Nurcan BEKTAŞ, Yusuf ÖZTÜRK

Aim: To identify the effects of antioxidants on gastrointestinal smooth muscle complications in 6-week streptozotocine
(STZ)-induced diabetic rats.
Materials and methods: The following steps were carried out: 1. Three weeks after STZ injection, saline and 10 mg/kg
p-OH benzoic, protocatechic, and gallic acids were separately administered to the rat groups every day for 3 weeks. 2.
The responses of the fundus and ileum to agonists were recorded using isolated organ bath experiments.
Results: Diabetic smooth muscle complications developed in the diabetic rats. The responses of the ileum to acetylcholine
increased whereas the responses of the fundus to serotonine decreased in the diabetic rats. The test drugs inhibited and
promoted but did not affect the smooth muscle complications in the diabetic rats, and sometimes they affected the
smooth muscle activity, which did not change with diabetes.
Conclusion: The antioxidants used elicited pro-oxidant activation and/or exhibited effects independent of diabetic
complications of gastrointestinal smooth muscles in the experimental conditions applied.
Key words: Diabetes mellitus, gastrointestinal tract complication, p-OH benzoic acid, protocatechic acid, gallic acid

Fenolik asitlerin streptozotosin ile diyabet oluşturulmuş sıçanlarda gelişen
gastrointestinal düz kas komplikasyonları üzerine etkileri
Amaç: Bu çalışma, antioksidanların streptozotosin (STZ) ile diyabet oluşturulmuş altı haftalık diyabetik sıçanlarda
gelişen gastrointestinal düz kas komplikasyonları üzerine etkilerini incelemeyi amaçlamıştır.
Yöntem ve gereç: Sırasıyla şu işlemler uygulanmıştır: 1. STZ enjeksiyonundan 3 hafta sonra; saline, 10 mg/kg p-OH
benzoik, protokateşik ve gallik asid, oluşturulan sıçan gruplarına üç hafta süresince ayrı ayrı uygulanmıştır. 2. İzole
fundus ve ileumun agonistlere karşı verdikleri cevaplar izole organ banyosu deneyleri kullanılarak kaydedilmiştir.
Bulgular: Diyabetik sıçanlarda düz kas komplikasyonları oluşmuştur. Diyabetik sıçanlarda, ileumun asetilkoline karşı
verdiği cevaplar artarken fundusun serotonine karşı verdiği cevaplar azalmıştır. Kullanılan fenoliklerin düz kaslarda
oluşan bu değişiklikleri önlediği, değiştirmediği veya ilerlettiği, kimi zaman ise diyabet ile bozulmayan düz kas
aktivitesinde değişikliklere neden oldukları belirlenmiştir.
Sonuç: Oluşturulan diyabetik koşullarda, kullanılan antioksidanların pro-oksidan aktivite gösterdiği ve/veya diyabetik
gastrointestinal düz kas komplikasyonlarından bağımsız etkiler sergilediği sonucuna varılmıştır.
Anahtar sözcükler: Diabetes mellitus, gastrointestinal sistem komplikasyonları, p-OH benzoik asid, protokateşik asid,
gallik asid
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Introduction
Diabetes mellitus affects the functions of various
smooth muscles as a long term complication and
conflicting response to several agonists in the
smooth muscles of experimentally diabetic animals,
suggesting the defective contractile process of smooth
muscle (1). One of the most important structural
changes in smooth muscles due to experimental
diabetes is autonomic neuropathy. As autonomic
nerves are highly integrated with smooth muscle
cells in various physiological systems, autonomic
neuropathy due to experimental diabetes may cause
consequent changes in smooth muscles (2,3). It
has been reported that increasing oxidative stress
during diabetes, largely due to hyperglycemia, has an
important role in the development of neuropathy, and
nerve damage may cause gastroenteropathy (4,5).
Phenolic acids are commonly found in plants and
their antioxidant potentials are well known. It has
been indicated that phenolic acids and the plants that
contain these compounds have antidiabetic activity
(6,7). The antioxidant activity of phenolic acids
correlated positively with the number of hydroxyl
groups bonded to the aromatic ring (8).
The present study aimed to evaluate the possible
effects of 3-week treatment with 10 mg/kg p-OH
benzoic acid (p-OHBA), protocatechic acid (PA),
and gallic acid (GA), which have antioxidant
activities with increasing potency order related to
their hydroxyl number, on diabetic smooth muscle
complications that developed in the gastrointestinal
tract. Experimental procedures were applied to the
ileum and fundus isolated from 6-week streptozotocin
(STZ)-induced diabetic rats by using isolated organ
baths.
Materials and methods
Experimental animals
Adult male Wistar rats (350-450 g) were used. The
animals were housed in a well ventilated room, on
12-h light/12-h dark cycle, and at 24 ± 1 °C. All
animals were allowed free access to standard pellet
diet (Eysem A. Ş., Eskişehir, Turkey) and water ad
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libitum. Animal care and research protocols were
based on the principles and guidelines adopted
by the Guide for the Care and Use of Laboratory
Animals (NIH publication No: 85-23, revised in
1985) and approved by the Local Ethics Committee
of Osmangazi University, Eskişehir.
Chemicals
Streptozotocin (Sigma, St. Louis, MO, USA), citric
acid (Merck, Darmstadt, Germany), trisodium citrate
(Merck), p-OH benzoic acid (Sigma), protocatechic
acid (Sigma), gallic acid (Sigma), phenylephrine.HCl
(Sigma), acetylcholine.HCl (Sigma), NaCl (Merck),
KCl (Merck), MgCl2 (Merck), KH2PO4 (Sigma),
NaHCO3 (Merck), Glucose.H2O (Merck), and
CaCl2.2H2O (Merck).
Diabetic model and experimental groups
Experimental diabetes was induced by a single i.v.
injection of STZ (50 mg/kg body wt.) into the tail
vein. STZ was dissolved in 0.1 mol/L citric acid buffer,
adjusted to pH 4.50 (9). Seventy-two hours after the
injection of STZ, blood glucose levels were measured
by Glukotrend® (Roche, Switzerland). The rats with
blood glucose levels above 300 mg/dL were considered
diabetic and were selected for the experiments. The
other rat group was injected with citric acid buffer
(i.v.) only, as the non-diabetic control group (n = 6).
Then STZ-diabetic rats were divided into 4 groups (n
= 6 per group). Three weeks after, the rats in the 1st
group were injected with (i.p.) 10 mg/kg p-OHBA,
those in the 2nd group were injected with 10 mg/kg
PA, and those in the 3rd group were injected with 10
mg/kg GA every day for 3 weeks. The last group, the
STZ-diabetic control group, was injected with (i.p.)
saline only. Blood glucose levels and the weights of
rats in all groups were measured at the same hours
every week.
Isolated organ bath experiments
The rats in all groups were sacrificed by cervical
dislocation 6 weeks after the induction of diabetes. The
gastric fundus and the longitudinal layer of the ileum
were rapidly dissected and placed in Krebs-Henseleit
solution (KHS) (g/L: NaCl 6.9544; KCl 0.3504; MgCl2
0.0952; KH2PO4 0.1633; NaHCO3 2.1002; glucose.
H2O 2.20; CaCl2.2H2O 0.36) (pH 7.4). After cleaning
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the adhering fat and connective tissues, the isolated
organs were mounted with a resting tension of 1.0
g in an isolated organ bath (Ugo-basile, 4050, Italy)
containing 10 mL of KHS, aerated with mixture of
95% O2 and 5% CO2 at 37 °C (10,11). The responses
of isolated organs were recorded isometrically using
a force-displacement transducer (Ugo-basile, 7003,
Italy) connected to a pen recorder (Ugo-basile, 7070,
Italy). The gastric fundus was firstly contracted with
10-9-10-3 mol/L acetylcholine (ACh) and then washed
3 or 4 times with KHS every 15 min, before exposure
to doses of 10-9-10-3 mol/L 5hydroxytryptamine (5HT). Concentration-response relationships of the
ileum were obtained with doses of 10-9-10-3 mol/L
ACh only.

Results

Statistical analysis

There was no significant difference between the
groups in pD2 values, which were calculated from the
contractile response of the fundus to ACh. Emax values
of the STZ-diabetic and GA-treated groups were
lower when compared to the non-diabetic control
group but this difference was not significant (Table
1). Moreover, statistically significant decreases were
observed in Emax values of p-OHBA and PA-treated
groups when compared to the non-diabetic and STZdiabetic groups (P < 0.001).
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STZ-diabetic rats exhibited characteristic symptoms
of diabetes such as polyuria, polydipsia, polyphagia,
and weight loss. Blood glucose concentrations in all
experimental groups were significantly (P < 0.001)
higher than those in the control group. The treatment
with p-OHBA, PA, and GA did not normalize
hyperglycemia that occurred through STZ-induced
diabetes (Figure 1). Weight loss can be seen in Figure
2. There were no significances between the treated
and STZ-diabetic groups.
Isolated organ bath experiments
Isolated fundus

pD2 and Emax values calculated from contractions
in the STZ-diabetic group in response to 5-HT
contraction were found to be decreased when
compared to those in the non-diabetic group (P <
0.05, P < 0.01) (Table 2). The injection of p-OHBA
partially normalized the pD2 value but the injections

***
***

***

***

Weight of body (g)

Blood Glucose Levels (mg/dL)

The contraction responses were expressed as
apparent affinity constant (pD2) and percentage
of the corresponding maximal responses to each
agonist [Emax (intrinsic activity)]. pD2 value is given
by the negative logarithm of the molar agonist
concentration that produces 50% of the maximal
response produced by the agonist (pD2 = –logEC50).
The statistical analyses were performed by one-way
ANOVA, followed by Tukey’s multiple comparison
tests. The statistical analyses were carried out using
GraphPad Prism version 5.0 and Microsoft Office
Excel. The results were expressed as the mean ±
S.D. to show variation in groups. Differences were
considered significant when P ≤ 0.05.

Blood glucose levels

C
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STZ+p-OHBA STZ+PA
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Figure 1. Blood glucose levels of non-diabetic control (C), STZdiabetic control (STZ), p-OHBA-treated (STZ+pOHBA), PA-treated (STZ+PA), and GA-treated
(STZ+GA) rats, ***P < 0.001; significance relative to C
(n = 6).
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Figure 2. Weight loss of non-diabetic control (C), STZ-diabetic
control (STZ), p-OHBA-treated (STZ+p-OHBA), PAtreated (STZ+PA), and GA-treated (STZ+GA) groups
(n = 6).
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Table 1. pD2 and Emax values obtained from non-diabetic control
(C), STZ-diabetic control (STZ), p-OHBA-treated
(STZ+p-OHBA), PA-treated (STZ+PA), and GAtreated (STZ+GA) groups’ fundus response to Ach (n
= 6).
pD2 ± S.D

Emax ± S.D

C

4.82 ± 0.40

100 ± 0.00

STZ

4.67 ± 0.19

97.41 ± 12.83

4.93 ± 0.19

***, ###

STZ+PA

4.56 ± 0.19

***, ###

STZ+GA

5.00 ± 0.25

STZ+p-OHBA

68.03 ± 11.52
71.27 ± 10.76

91.33 ± 15.68

Table 2. pD2 and Emax values obtained from non-diabetic control
(C), STZ-diabetic control (STZ), p-OHBA-treated
(STZ+p-OHBA), PA-treated (STZ+PA), and GAtreated (STZ+GA) groups’ fundus response to 5-HT (n
= 6).
pD2 ± S.D.

Emax ± S.D.

C

5.99 ± 0.46

100 ± 0.00

STZ

*

**

5.36 ± 0.23

STZ+p-OHBA

5.66 ± 0.22

STZ+PA

*

STZ+GA

**

79.51 ± 13.14

***, ###

55.01 ± 5.90

***

5.42 ± 0.18

*

5.33 ± 0.13

63.76 ± 15.41

77.76 ± 18.81

***

P < 0.001; significance relative to C, ### P < 0.001; significance
relative to STZ

*

of PA and GA did not affect the diabetes induced
impairment. Emax values of the treatment groups were
not significantly close to the Emax value of the control
group even the Emax value of the p-OHBA-treated
group (P < 0.001), whereas the PA- and GA-treated
groups were partially decreased when compared to
the STZ-diabetic group.

Table 3. pD2 and Emax values obtained from non-diabetic control
(C), STZ-diabetic control (STZ), p-OHBA-treated
(STZ+p-OHBA), PA-treated (STZ+PA), and GAtreated (STZ+GA) groups’ ileum response to ACh (n =
6).

Isolated ileum
pD2 and Emax values of the STZ-diabetic group were
increased significantly compared to those of the
non-diabetic group (P < 0.05, P < 0.001) (Table 3).
The administrations of test drugs did not normalize
the pD2 values relative to the STZ-diabetic group.
However, statistically significant decreases were
observed in Emax values of all treatment groups (P <
0.001) even the Emax values of the p-OHBA and PAtreated groups were decreased when compared to the
non-diabetic group.
Discussion
Contraction and relaxation capacities of
gastrointestinal smooth muscles change due to the
impairment effect of diabetes (2). Experimental
studies have indicated that adrenergic, cholinergic,
and serotonergic stimulations of smooth muscles
were damaged because of diabetes (12). However,
the findings obtained from diabetic animal models
seem to be conflicting (13). Increased, decreased,
or unchanged contractions of smooth muscles
214

P < 0.05, ** P < 0.01, *** P < 0.001; significance relative to C, ### P
< 0.001; significance relative to STZ

pD2 ± S.D.

Emax ± S.D.

C

4.79 ± 0.53

100 ± 0.00

STZ

*

STZ+p-OHBA

*

STZ+PA

*

STZ+GA

**

5.66 ± 0.25

***

151.40 ± 18.46

5.56 ± 0.58

**, ###

5.48 ± 0.42

*, ###

5.74 ± 0.38

72.87 ± 12.42

###

74.69 ± 13.01

105.70 ± 17.29

*

P < 0.05, ** P < 0.01, *** P < 0.001; significance relative to C, ### P
< 0.001; significance relative to STZ

have been observed in various studies (14-17).
However, serotonin-induced contractions of isolated
gastric fundus have been reported to be decreased
significantly in both alloxan and STZ-diabetic rats
as in our study (14). In addition, in our study, the
cholinergic responsiveness did not change in the
gastric fundus whereas it increased significantly in
the ileum of 6-week STZ-diabetic rats. Our results are
in general agreement with a group of studies, while
conflicting with some other studies. The reasons for
these controversies are not clear but are generally
attributed to differences in the diabetic agents used,
the duration of diabetes, the sex of the animals,
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the animal strains, and the techniques applied for
measuring and expressing contractile force. Since
pD2 and Emax values indicate the changes in receptor
affinity and intrinsic activity, respectively (18), the
changes in intestinal smooth muscle contractions
were attributed to changes in the affinity, and either
the number of receptors or the activity of the postreceptor mechanisms or both.
The impairments in the activities of protein
kinase C, calcium channels, diacylglycerol dependent
protein kinase, Na+,K+-ATPase, calcium influx, and
sensitivity and/or affinity of calmodulin in intestinal
smooth muscles may be responsible for these
changed post-receptor mechanisms, since there are
many studies that indicate that these mechanisms are
affected by diabetes (14,15,19,20). It has also been
reported that the structural alterations in diabetic
ileum and G proteins in diabetic fundus may be
involved in impaired functions of gastrointestinal
smooth muscles in experimental diabetes (17,21).
However, the underlying causes of impaired
contractile responses of the gastric fundus to ACh
and 5-HT and of the ileum to ACh require further
investigation.
Since the relationship between DM and oxidative
stress is known, it is thought that impairment of nerve
conduction may be due to increased oxidative stress,
and nerve damage may cause gastroenteropathy
(22). Treatment with antioxidants may prevent or
ameliorate abnormal functions and biochemistry
of nerves, and also protects nerves from free
radical damage (23). Thus antioxidants may have a
potential to prevent gastroenteropathy. In contrast,
in the present study, p-OHBA, PA, and GA generally
showed impairing effects in STZ-diabetic fundus and
ileum as explained in the results section. These effects
were inversely correlated with –OH numbers in the

molecules of antioxidants. Based on these results,
it was concluded that the demonstrated preventive
effects of the test drugs developed independently of
antioxidant potential and diabetic complications.
Moreover, since the damaging effects of the
antioxidants used were observed, it was thought
that these antioxidants may act like pro-oxidants
in our experiment conditions. It has already been
indicated that various phenolic acids such as GA
may have pro-oxidant effects in different conditions
(24,25). It is known that pro-oxidant activity of
phenolics increases in the presence of redox active
metal ions such as Fe++ and Cu++ and levels of these
metal ions change in diabetic conditions (26,27).
Polyphagia and metabolic changes in diabetic rats
cause accumulation of metal ions in tissues (28).
These metabolic changes were observed in our study.
Conversely to accumulation of these metal ions, Zn++
ions, which have a role in preventing Fe++ and Cu++
-initiated lipid peroxidation, decrease in diabetes as a
symptom of the disease (29,30). Thus, changed levels
of all of these ions may have affected the test drugs’
actions in our study.
Taking these findings into account, it seems
possible that p-OHBA, PA, and GA showed prooxidant characteristics, since it is demonstrated
that the levels of Fe++ and Cu++ increased and Zn++
decreased in diabetic conditions. However, detailed
investigations are needed to clarify the occurrence of
the conditions when antioxidants act as pro-oxidants
in the same experimental design used in this study.
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